Skip to main content
AI Market Summary
Loading market intelligence...

ATRION CORP (ATRI) Stock Forecast 2025 - AI Price Prediction & Analysis


ATRION CORP (ATRI) AI Stock Price Forecast & Investment Analysis

ATRION CORP Stock Price Chart and Technical Analysis

Loading ATRION CORP interactive price chart and technical analysis...

ATRION CORP (ATRI) - Comprehensive Stock Analysis & Investment Research

Deep dive into ATRION CORP's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about ATRION CORP, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For ATRION CORP: ATRION CORP operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

ATRION CORP (Stock Symbol: ATRI) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 4 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing ATRION CORP's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For ATRION CORP: With $181M in annual revenue and 6.9% net margin, the company demonstrates solid profitability.

Annual Revenue: $181 million generating a 6.9% net profit margin .

Market Capitalization: $1572 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): 13.8% - Above-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for ATRION CORP stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For ATRION CORP: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for ATRION CORP stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: ATRION CORP's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For ATRION CORP: Strong free cash flow generation demonstrates developing operational efficiency.

ATRION CORP strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company demonstrates robust operational efficiency through strong free cash flow generation of $23 million annually, complemented by impressive -7.6% year-over-year cash flow growth.

The company maintains a healthy -2.2% gross margin, indicating strong pricing power and operational efficiency.

ATRION CORP (ATRI) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for ATRION CORP stock analysis.

Loading ATRION CORP comprehensive fundamental analysis and insider trading data...

Deep dive into ATRION CORP's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if ATRION CORP stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For ATRION CORP: With a P/E ratio of 47.29, the market highly values future growth prospects.

P/E Ratio 47.29x
P/B Ratio 6.58x
Market Cap $1572M
Dividend Yield 0.01%
EPS $7.13
Book Value/Share $69.88
Revenue/Share $3.64
FCF/Share $8.08
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently ATRION CORP converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For ATRION CORP: An ROE of 13.8% shows good shareholder value creation.

ROE 13.8%
ROA 12.5%
ROIC 13.5%
Gross Margin -2.2%
Operating Margin -4.5%
Net Margin 6.9%
EBT Margin 22.7%
Tax Rate 14.0%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess ATRION CORP's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For ATRION CORP: A current ratio of 8.57 indicates strong liquidity.

Current Ratio 8.57x
Quick Ratio 5.22x
Financial Leverage 1.10x
Working Capital $99M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal ATRION CORP's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For ATRION CORP: Free cash flow of $23M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow $43M
Free Cash Flow $23M
Capital Spending $-20M
OCF Growth YoY -7.6%
FCF Growth YoY -21.3%
FCF/Sales 13.2%
CapEx/Sales 11.8%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively ATRION CORP uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For ATRION CORP: An asset turnover of 0.64x suggests room for improvement in asset utilization.

Asset Turnover 0.64x
Receivables Turnover 7.8x
Inventory Turnover 2.0x
Fixed Assets Turnover 1.8x
Days Sales Outstanding 47 days
Days Inventory 183 days
Payables Period 43 days
Cash Conversion Cycle 187 days
Understanding Financial Statement Data

What these metrics mean: Key figures from ATRION CORP's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For ATRION CORP: With annual revenue of $181M, ATRION CORP demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $181M
Operating Income $-8M
Net Income $12M
R&D Expense $0M
SG&A Expense $17M
Cost of Goods Sold $17M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 51%
Cash & Short-term Investments 22%
Total Liabilities 9%
Accounts Receivable 9%
Inventory 19%
Dividend & Shareholder Information
Dividends Per Share $6.55
Payout Ratio 0.9%
Shares Outstanding 3M
Growth Metrics (YoY)
EPS Growth 1.6%

Latest ATRION CORP Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting ATRION CORP (ATRI) stock price and investment outlook.

, source: Nasdaq

Looking at the universe of stocks we cover at Dividend Channel, on 3/14/22, CONMED Corp (Symbol: CNMD), Atrion Corp. (Symbol: ATRI), and KBR Inc (Symbol: KBR) will all trade ex-dividend for their ...

, source: Forbes

Looking at the universe of stocks we cover at Dividend Channel, on 11/29/12, Atrion Corp. (NASD: ATRI) will trade ex-dividend, for its quarterly dividend of $0.56, payable on 12/17/12. As a percentage ...

, source: PR Newswire

EmergingGrowth.com, a leading digital financial media company, Reports on Atrion Corp. Discussion also includes Johnson & Johnson, Tyco International, Baxter International, and Covidien Plc. In the ...

ATRION CORP Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of ATRION CORP against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $15M x 1.6x
AEMD Unlock Forecast - 30 Days FREE Trial $9M -0.1x 1.6x
ALUR Unlock Forecast - 30 Days FREE Trial $13M -0.4x -0.3x
AMIX Unlock Forecast - 30 Days FREE Trial $2M x 0.3x
ANGO Unlock Forecast - 30 Days FREE Trial $545M -1.4x 3.0x
ANIK Unlock Forecast - 30 Days FREE Trial $138M -4.3x 0.9x
AORT Unlock Forecast - 30 Days FREE Trial $2075M -198.2x 4.7x
APYX Unlock Forecast - 30 Days FREE Trial $146M -3.5x 25.0x
ARAY Unlock Forecast - 30 Days FREE Trial $120M -9.9x 1.9x
ATEC Unlock Forecast - 30 Days FREE Trial $2981M -7.4x 259.1x
ATRC Unlock Forecast - 30 Days FREE Trial $2107M -39.6x 4.4x
AVHHL Unlock Forecast - 30 Days FREE Trial $24M x x
BAX Unlock Forecast - 30 Days FREE Trial $9843M -94.9x 1.4x
BBNX Unlock Forecast - 30 Days FREE Trial $1309M x 4.4x
BDX Unlock Forecast - 30 Days FREE Trial $57959M 34.5x 2.3x
BEAT Unlock Forecast - 30 Days FREE Trial $79M -5.7x 194.5x
BJDX Unlock Forecast - 30 Days FREE Trial $2M -0.5x 0.5x
BSX Unlock Forecast - 30 Days FREE Trial $138315M 49.4x 5.9x
BTCY Unlock Forecast - 30 Days FREE Trial $9M -2.7x -0.1x
BVS Unlock Forecast - 30 Days FREE Trial $519M 66.4x 3.1x
CARL Unlock Forecast - 30 Days FREE Trial $130M x 1.2x
CERS Unlock Forecast - 30 Days FREE Trial $414M -13.8x 6.7x
CLPT Unlock Forecast - 30 Days FREE Trial $361M -23.5x 22.8x
CODX Unlock Forecast - 30 Days FREE Trial $16M -0.7x 0.4x
CTSO Unlock Forecast - 30 Days FREE Trial $43M -1.8x 4.8x
CVRX Unlock Forecast - 30 Days FREE Trial $221M -5.5x 4.6x
DCTH Unlock Forecast - 30 Days FREE Trial $366M 305.6x 3.2x
DHAI Unlock Forecast - 30 Days FREE Trial $0M x -0.3x
DRIO Unlock Forecast - 30 Days FREE Trial $552M 0.6x 7.4x
DRTS Unlock Forecast - 30 Days FREE Trial $429M x 5.0x
DXCM Unlock Forecast - 30 Days FREE Trial $26114M 36.2x 9.6x
DYNT Unlock Forecast - 30 Days FREE Trial $1M -0.2x 0.2x
EBRCZ Unlock Forecast - 30 Days FREE Trial $272M x 7.0x
ECIA Unlock Forecast - 30 Days FREE Trial $3M x 1.7x
EMBC Unlock Forecast - 30 Days FREE Trial $690M 7.2x -0.8x
EMED Unlock Forecast - 30 Days FREE Trial $0M x x
FEMY Unlock Forecast - 30 Days FREE Trial $41M -1.4x 8.9x
FOFA Unlock Forecast - 30 Days FREE Trial $8M x 10.0x
GCTK Unlock Forecast - 30 Days FREE Trial $5M 0.9x 1.9x
GIPL Unlock Forecast - 30 Days FREE Trial $5M x 25.8x
GKOS Unlock Forecast - 30 Days FREE Trial $6248M -46.3x 8.1x
GMED Unlock Forecast - 30 Days FREE Trial $11897M 28.1x 2.7x
GUTS Unlock Forecast - 30 Days FREE Trial $122M x 13.8x
HAE Unlock Forecast - 30 Days FREE Trial $3903M 23.2x 4.6x
HRGN Unlock Forecast - 30 Days FREE Trial $35M x 22.3x
IART Unlock Forecast - 30 Days FREE Trial $1028M 200.2x 1.0x
ICCM Unlock Forecast - 30 Days FREE Trial $39M x 13.5x
ICU Unlock Forecast - 30 Days FREE Trial $11M -1.1x 1.0x
ICUI Unlock Forecast - 30 Days FREE Trial $3664M -49.8x 1.7x
IDXG Unlock Forecast - 30 Days FREE Trial $6M 1.3x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $28M x 6.5x
IINNW Unlock Forecast - 30 Days FREE Trial $6M x 1.5x
INBS Unlock Forecast - 30 Days FREE Trial $5M -0.3x 1.4x
INFU Unlock Forecast - 30 Days FREE Trial $188M 34.0x 3.4x
INSP Unlock Forecast - 30 Days FREE Trial $3797M 85.2x 5.7x
IRMD Unlock Forecast - 30 Days FREE Trial $1224M 57.8x 12.5x
IRTC Unlock Forecast - 30 Days FREE Trial $5437M -20.2x 44.6x
KIDS Unlock Forecast - 30 Days FREE Trial $412M -20.7x 1.2x
KMTS Unlock Forecast - 30 Days FREE Trial $1344M x x
KRMD Unlock Forecast - 30 Days FREE Trial $268M -19.8x 16.3x
LMAT Unlock Forecast - 30 Days FREE Trial $1925M 36.1x 5.1x
LNSR Unlock Forecast - 30 Days FREE Trial $137M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $152M -0.6x 5.9x
LUNG Unlock Forecast - 30 Days FREE Trial $104M -4.3x 1.7x
LYRA Unlock Forecast - 30 Days FREE Trial $6M -0.1x 4.6x
MBOT Unlock Forecast - 30 Days FREE Trial $93M -1.3x 1.2x
MCAG Unlock Forecast - 30 Days FREE Trial $34M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $31M x -9.9x
MDAI Unlock Forecast - 30 Days FREE Trial $44M -1.3x -42.3x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.2x 12.2x
MDXG Unlock Forecast - 30 Days FREE Trial $1069M 26.2x 4.5x
MGRM Unlock Forecast - 30 Days FREE Trial $217M -10.7x 25.1x
MHUA Unlock Forecast - 30 Days FREE Trial $216M x 1.3x
MMM Unlock Forecast - 30 Days FREE Trial $89724M 26.4x 19.4x
MMSI Unlock Forecast - 30 Days FREE Trial $5140M 43.4x 3.4x
MODD Unlock Forecast - 30 Days FREE Trial $21M -2.1x 2.4x
NEPH Unlock Forecast - 30 Days FREE Trial $53M 36.0x 6.4x
NMTC Unlock Forecast - 30 Days FREE Trial $24M -1.7x 3.0x
NPCE Unlock Forecast - 30 Days FREE Trial $539M -10.4x 29.1x
NSPR Unlock Forecast - 30 Days FREE Trial $82M -4.3x 1.3x
NUMD Unlock Forecast - 30 Days FREE Trial $2M x x
NVCR Unlock Forecast - 30 Days FREE Trial $1492M -20.8x 4.4x
NXGL Unlock Forecast - 30 Days FREE Trial $14M -6.8x 2.6x
OBIO Unlock Forecast - 30 Days FREE Trial $255M -3.4x 2.6x
ODYY Unlock Forecast - 30 Days FREE Trial $4M x x
OFIX Unlock Forecast - 30 Days FREE Trial $612M -5.8x 1.4x
OSRH Unlock Forecast - 30 Days FREE Trial $15M x 0.2x
OSUR Unlock Forecast - 30 Days FREE Trial $180M 17.1x 0.5x
PAVM Unlock Forecast - 30 Days FREE Trial $8M 2.5x 0.2x
PDEX Unlock Forecast - 30 Days FREE Trial $142M 12.6x 3.4x
PEN Unlock Forecast - 30 Days FREE Trial $12247M 74.7x 9.0x
PETV Unlock Forecast - 30 Days FREE Trial $37M -1.4x 8.8x
PLRZ Unlock Forecast - 30 Days FREE Trial $74M x 4.0x
PLSE Unlock Forecast - 30 Days FREE Trial $965M -2.6x 10.4x
PMI Unlock Forecast - 30 Days FREE Trial $22M x 2.8x
PODD Unlock Forecast - 30 Days FREE Trial $21377M 86.8x 15.5x
PRCT Unlock Forecast - 30 Days FREE Trial $2011M -45.4x 5.3x
PROF Unlock Forecast - 30 Days FREE Trial $221M x 6.9x
PSTV Unlock Forecast - 30 Days FREE Trial $17M -0.3x 3.4x
PYPD Unlock Forecast - 30 Days FREE Trial $24M x 1.2x
RCEL Unlock Forecast - 30 Days FREE Trial $106M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $33M x 15.0x
RMD Unlock Forecast - 30 Days FREE Trial $36816M 25.6x 6.0x
RSMDF Unlock Forecast - 30 Days FREE Trial $3977M 2.8x 0.7x
RTGN Unlock Forecast - 30 Days FREE Trial $60M x x
RVP Unlock Forecast - 30 Days FREE Trial $25M -0.9x 0.3x
SGHT Unlock Forecast - 30 Days FREE Trial $425M -3.7x 6.6x
SIBN Unlock Forecast - 30 Days FREE Trial $804M -14.3x 4.7x
SIGY Unlock Forecast - 30 Days FREE Trial $3M x x
SKIN Unlock Forecast - 30 Days FREE Trial $178M -1.8x 2.7x
SNOA Unlock Forecast - 30 Days FREE Trial $6M -5.6x 1.6x
SNWV Unlock Forecast - 30 Days FREE Trial $270M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $14392M 9.4x 2.9x
SRTS Unlock Forecast - 30 Days FREE Trial $63M 31.6x 1.2x
SSKN Unlock Forecast - 30 Days FREE Trial $7M -8.0x 5.7x
STIM Unlock Forecast - 30 Days FREE Trial $104M -1.0x 3.8x
STME Unlock Forecast - 30 Days FREE Trial $16M x x
STSS Unlock Forecast - 30 Days FREE Trial $74M -2.5x 0.2x
SYK Unlock Forecast - 30 Days FREE Trial $136856M 46.5x 11.7x
TCMD Unlock Forecast - 30 Days FREE Trial $621M 34.2x 3.0x
TELA Unlock Forecast - 30 Days FREE Trial $46M -1.8x 29.8x
TFX Unlock Forecast - 30 Days FREE Trial $5679M 31.0x 1.5x
TLSI Unlock Forecast - 30 Days FREE Trial $364M -3.6x -5.6x
TLSIW Unlock Forecast - 30 Days FREE Trial $72M x -1.9x
TMCI Unlock Forecast - 30 Days FREE Trial $177M -7.5x 2.0x
TNDM Unlock Forecast - 30 Days FREE Trial $1450M -17.1x 10.9x
TNON Unlock Forecast - 30 Days FREE Trial $10M -0.3x 2.1x
UFPT Unlock Forecast - 30 Days FREE Trial $1692M 25.2x 4.2x
USAQ Unlock Forecast - 30 Days FREE Trial $3M x x
UTMD Unlock Forecast - 30 Days FREE Trial $186M 16.0x 1.6x
VERO Unlock Forecast - 30 Days FREE Trial $3M 0.0x 1.3x
VYCO Unlock Forecast - 30 Days FREE Trial $5M x x
WST Unlock Forecast - 30 Days FREE Trial $19238M 39.1x 6.3x
XAIR Unlock Forecast - 30 Days FREE Trial $91M -0.3x 7.2x
XTNT Unlock Forecast - 30 Days FREE Trial $102M 58.0x 2.0x

Frequently Asked Questions - ATRION CORP Stock Forecast

How accurate are ATRION CORP stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for ATRI predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence ATRION CORP stock price forecasts?

Our analysis considers ATRION CORP's financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is ATRION CORP a good investment in 2025?

Based on our AI analysis, ATRION CORP shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are ATRION CORP forecasts updated?

ATRION CORP stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced ATRION CORP Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for ATRION CORP stock.

My Portfolio

Investment Dashboard

Loading your portfolio...